08nav3.jpg
Beyond Genome 2008
Register Now
Travel Information
Poster Information
CD Orders
Downloads
Hotel and Travel Information
Request Information
Visit Healthtech.com
Conference Programs
Short Courses
Short Courses
Sponsorship Information
Exhibit Information
Media Partners
Press Information


ABSTRACTION
June 10-11

Short Courses | Day 1 | Day 2 | Download Brochure

12:00 pm Registration Open

2:00 Chairperson’s Remarks

Keynote Presentation
2:05 Optimizing Target Portfolios: Systems Biology Approaches
David de Graaf, Ph.D., Director, Systems Biology, Pfizer Inc.

2:35 Mechanisms of Toxicity 
Keith Elliston, Ph.D., President & CEO, Genstruct Inc.

3:05 Large Scale in silico Animal Model Expedites Discovery of Optimal Treatments for Type 1 Diabetes
Saroja Ramanujan, Ph.D., Associate Director, In Silico Research and Development, Entelos
Matthias von Herrath, M.D., Member, Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology
To date, no single pharmacologic agent has been identified that can reverse the onset of human type 1 diabetes (T1D). Combinations of existing agents are promising treatment strategies; however the uncertainty of optimal dosing regimens can greatly reduce the efficiency of laboratory studies. The collaborative research between the ADA/Entelos Diabetes Research Center (DRC) and Dr. Matthias von Herrath’s lab at the La Jolla Institute for Allergy and Immunology (LIAI) used a combined in silico/laboratory approach to identify optimal combination therapies to reverse diabetes onset in non-obese diabetic (NOD) mice. Using the T1D PhysioLab® platform, a large-scale mathematical model of T1D pathogenesis in the NOD mouse, variations in dosing and timing were simulated to identify treatment protocols that maximize the likelihood of observing diabetes reversal in the laboratory. The simulation results predicted optimal dosing regimens for oral insulin/anti-CD3 and oral insulin/exendin-4 combination therapies. By conducting laboratory experiments directly informed by in silico simulations, LIAI has been able to optimize its research design and expedite the discovery of type 1 diabetes therapeutics.

3:35 Technology Spotlight (Sponsorship Available)

3:50 Networking Refreshment Break, Poster and Exhibit Viewing

4:30 Dialogue on Reverse Engineering Assessment and Methods: the DREAM of High Throughput Pathway Inference 
Gustavo A. Stolovitzky, Ph.D., Adj. Associate Professor of Biomedical Informatics, Columbia University & Manager, Functional Genomics & Systems Biology, IBM Research 
The biotechnological advances of the last decade have confronted us with an explosion of data that need to be organized and structured before they may provide a coherent biological picture. To accomplish this task, the availability of an accurate map of the physical interactions in the cell that are responsible for cellular behavior and function would be exceedingly helpful, as these data are ultimately the result of such molecular interactions. However, all we have at this time is partially correct representation of the interactions between genes, their byproducts, and other cellular entities. DREAM, the Dialogue on Reverse Engineering Assessment and Methods, is fostering a concerted effort by computational and experimental biologists to understand the limitations and enhance the strengths of the efforts to reverse engineering cellular networks from high throughput data. In this talk I will discuss the salient arguments of the recent DREAM2 conference, where we challenged the community to blindly infer networks known to the organizers from high throughput data. I will highlight the strategies that have achieved the better inference results and discuss the state of the art in Reverse Engineering, as well as some of the challenges and opportunities awaiting us. 

5:00 BetaWorkbench: An Innovative Framework for Systems Modeling, Simulation and Analysis 
Corrado Priami, Ph.D., President & CEO, Computational and Systems Biology, Microsoft Research - University of Trento Centre for Computational and Systems Biology 
The talk will present new stochastic techniques to model and analyse genomic signalling networks as well as new software prototypes based on these techniques. The basic idea is that any biological element is represented as a program and the interaction between the elements is modeled as a message passing between the corresponding programs. This metaphor allows us to reuse concurrency theory developed in computer science in the last 30 years to study the behaviour of distributed software running on computer networks into the biology applicative domain. 

5:30 Close of Day

Short Courses | Day 1 | Day 2 | Download Brochure



Download the 
Final
Brochure

Premier
Sponsor:

Corporate
Sponsor:

Lead Sponsoring
Publications